Verastem, Inc. (VSTM) · Nov 5, 2026 · Earnings
Miss — $24M net product revenue vs ~$26.57M consensus
Verastem’s Q3 earnings show AVMAPKI revenue below expectations, while new financing extends the runway to pursue its KRAS G12D pipeline.
Verastem is a commercial-stage oncology biotech: AVMAPKI FAKZYNJA CO-PACK is generating initial U.S. revenue, while the company is building VS-7375 into a multi-tumor KRAS G12D franchise. The prior quarter established a roughly $25.1 million AVMAPKI revenue base and a cash runway into the second half of 2027, so this update was mainly about whether commercial momentum was accelerating and whether the pipeline was funded.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net product revenue (Financial Summary) | $24.0M | ~$26.57M | |
| GAAP operating expenses (Financial Summary) | $99.2M | ||
| Non-GAAP operating expenses (Financial Summary) | $95.2M | ||
| Pro forma cash (Financial Summary) | $422.8M |
The commercial launch did not clear the near-term bar. AVMAPKI net product revenue was $24 million, below the published consensus of about $26.57 million, making this an earnings miss rather than evidence of accelerating uptake. The company says demand held steady after Q2’s growth, but “steady” is weaker than the market’s apparent expectation for another step-up. 〔0〕
The balance sheet materially reduces execution pressure. Pro forma cash reached $422.8 million after the October equity offering and financing arrangements, with management projecting runway into the first half of 2028. That gives Verastem time to fund the pivotal RAMP 301 readout and advance VS-7375, but it is financing-supported runway—not proof that product revenue is yet covering the investment cycle.
The pipeline remains the stronger part of the story, but much of this evidence was already public. The slides repeat encouraging early VS-7375 response and tolerability data across pancreatic, lung, and colorectal cancers, while the key near-term value driver remains the confirmatory RAMP 301 trial. The filing gives a mid-2027 topline timing, and the blister-pack NDA has Priority Review with a February 7, 2027 PDUFA date. 〔1〕 〔2〕
Bottom line: This was a modest earnings miss wrapped in a much stronger funding update. The business story is not overturned, but near-term commercial execution is softer than expected while the company has bought substantial time to reach its major clinical and regulatory milestones.
FDA decision on blister-pack NDA, February 7, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!